France claims victory on EU online child protection guidelines
On Monday, the Commission unveiled much-anticipated guidelines for protecting minors online, as part of the Digital Services Act (DSA).
The initiative has drawn significant attention and backing from EU countries, industry, and children's rights groups, many of which have already set out their own positions in anticipation of the official DSA guidelines.
A French-led movement of EU countries seeking to ban social media for kids under 15 believes its position has been affirmed in the final Commission guidelines – a shift from an earlier draft, released in May, which did not clarify this issue.
"The European Commission has just confirmed the possibility for Member States to ban social networks for those under a certain age," French President Emmanuel Macron wrote in a triumphant post on X on Monday evening.
"This marks an important victory for France," added the country's digital minister, Clara Chappaz, in a press release which also stated that the guidelines have paved the way for banning social media for kids. Choose your own digital majority The final guidelines allow member countries to set their own so-called "digital majority" age, instead of establishing one at the EU level. On Monday, Tech Commissioner Henna Virkkunen said that creating an EU-wide digital majority is not possible due to "different cultures" and "differences between member states."
Danish Minister for Digital Affairs, Caroline Stage Olsen, who on Monday presented the guidelines alongside Virkkuen, stressed that age verification is "absolutely essential" – referencing the Commission's prototype age verification tool, which could underpin country-specific apps capable of restricting content deemed inappropriate for children.
EU lawmaker Christel Schaldemose, who is currently finalising a Parliamentary report on the protection of minors, also welcomed the Commission approach – saying she's "particularly glad that Member States retain the flexibility to implement their own age verification systems for social media."
However, she added that she would still like the Commission to adopt a "more ambitious stand on age verification" for social media platforms.
Children's rights groups also welcomed the guidelines. Manon Baert, from the 5Rights Foundation, said they "have the potential to make a real difference for children across Europe", adding: "Now companies must deliver."
But industry representatives are unhappy, with tech lobbies warning that allowing EU countries to decide their own digital majority age risks fragmentation.
"The door is still open for national laws, which is disappointing," said DOT Europe, a Brussels-based association representing Big Tech.
Meta, which has lobbied strongly for an EU-wide digital age majority alongside enhanced parental controls, also cautioned against introducing varying rules across countries.
(nl, aw)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
5 hours ago
- Euractiv
Greek pharma sector braces for US tariff fallout, patients risk first impact
Greek pharmaceutical and medical technology executives have voiced growing concern over the anticipated extension of US tariffs to medicines and medtech products, warning that the move could severely disrupt innovation, fracture supply chains, and curtail patient access - particularly in smaller EU markets such as Greece. Industry leaders argue that the proposed measures risk undermining competitiveness and investment at a time when Europe is striving to strengthen its strategic autonomy in healthcare. Following the announcement of the EU-US trade deal and the impending outcome of the Section 232 investigation, Greek industry voices are calling for urgent clarity and exemptions for critical health products. They point out that the evolving US trade strategy and an insufficient EU reaction will significantly impact Greece, due to a challenging operating environment, ultimately impeding access to therapies and medical technology products. 'Imposing tariffs either by the US alone or by both sides, Greece is expected to suffer a significant blow,' Olympios Papadimitriou, President of the Hellenic Association of Pharmaceutical Companies (SfEE), told Euractiv. Fundamental risk for Greece Papadimitriou points to the overburdened pharmaceutical environment in Greece, which is struggling with mandatory returns and insufficient funding, as the main factor that could amplify the implications of US tariffs. '[Greece] is the country with the worst environment for on-patent medicines in the European Union (lowest prices and highest refunds). If economic pressure starts a chain of all kinds of cuts, Greece will be among the first to suffer the consequences,' he remarked. These developments are expected to have the greatest impact on patients. As Labrina Barmpetaki, President of Pharma Innovation Forum (PIF), explained to Euractiv, if the appropriate action isn't taken, 'there is a growing risk of launch sequence prioritisation, where smaller EU countries, such as Greece, could be deprioritised or excluded altogether from access to new medicines.' Some generics are exempt from the imposed US tariffs. However, the full impact remains uncertain as key elements are still unclear, and the anticipated imbalance caused by implementing tariffs threatens to disrupt supply chains. 'For Greece's export-oriented pharmaceutical sector, such tariffs would undermine future competitiveness and challenge established transatlantic flows,' Theodoros Tryfon, President, Panhellenic Union of Pharmaceutical Industries (PEF), tells Euractiv, adding that the generic industry is looking forward to further clarity on the scope of products to be exempted. The biotechnology industry also underlines the risks of delays, higher costs, and reduced patient access due to potential tariffs on medical technology, which includes medical devices and in vitro diagnostics. 'Potential tariffs or restrictions on the movement of these products could lead to significant delays in the availability of life-saving technologies, increased healthcare costs, and jeopardised access to modern and effective solutions for patients,' the Hellenic Association of Medical and Biotechnological Product Enterprises (SEIV) notes in a statement to Euractiv. For SEIV, patient health must not be used as a bargaining chip in trade disputes. 'Delays in the supply of critical medical technology products can have a direct impact on the quality and timeliness of care, particularly in countries with limited resources or heavy reliance on imported technologies.' Risks across the EU and the Atlantic The implications of imposing export duties on pharmaceuticals will be far-reaching. Barbetaki notes the concerns about added strain on public healthcare systems, particularly in Europe, where access to medicines is largely state-funded. 'Such a shift could carry social and budgetary consequences if it disrupts the flow or affordability of essential treatments', she adds, highlighting that Europe faces structural hurdles in attracting pharma investment, especially compared to the US, which offers stronger funding, IP protection, faster regulation, and better innovation incentives. Its market-driven healthcare model also gives it a clear competitive edge, Barbetaki points out. As Papadimitriou notes, tariffs on medicines are a blunt instrument that will disrupt supply chains, impact investment in R&D, and ultimately harm patient access to medicines on both sides of the Atlantic. 'Any tariffs risk worsening existing shortages and further straining supply chains,' Tryfon warns, adding that Europe has consistently proven to be a reliable supplier to the US, particularly for critical medicines where it often serves as the main or only alternative to Asia. Regarding medical technology, despite earlier assurances and expectations, the sector wasn't mentioned in the official announcement, with the products exempted based on the EU-US 'zero-for-zero' trade agreement. However, efforts are still underway for a last-minute change. Redisigned approach needed 'If the intent is to secure pharmaceutical investment in research, development and manufacturing, rebalance trade and ensure a fairer distribution of how global pharmaceutical innovation is financed, then there are more effective means than tariffs that would help, rather than hinder, global advances in patient care and economic growth,' Papadimitriou argues. He explains, from a European perspective, that means 'rethinking how we value innovation, significantly increasing what the region spends on innovative medicines and creating an operating environment that can accelerate turning Europe's great science into new treatments.' Barbetaki is on the same page: 'To remain globally competitive, Europe will need to strengthen its policy framework by supporting innovation, upholding strong IP protections, ensuring regulatory clarity, and aligning environmental and industrial legislation.' However, she adds that Europe should also reconsider its approach to pricing policies and cost-containment measures, 'aiming for a different model to remain attractive for global pharmaceutical launches.' The Greek pharmaceutical industry advocates for the exemption of EU-origin generics, biosimilars, and APIs, as Tryfon remarks. 'The EU and US essential medicines lists significantly overlap, which highlights the necessity for a tariff exemption on products that ensure uninterrupted patient access and are crucial for reinforcing transatlantic health resilience,' Tryfon explains. Exemption is also crucial for medtech provision. SEIV sent a letter to the Greek Ministry of Health and Greek Members of the European Parliament earlier in July, stressing the need for active support to exempt medical technology products from any trade or tariff measures. It followed a joint letter from MedTech Europe and the US-based AdvaMed to European Commission President Ursula von der Leyen, expressing strong concern over the exclusion of the sector from the list of industries included in the 'zero-for-zero' trade agreement. Greek MEPs weigh in From an economist's point of view in a modern, globalised world, tariffs do not make sense, S&D and PASOK MEP Nikos Papandreou told Euractiv, noting that they are used as a weapon, 'to force trading partners to do things they wouldn't do otherwise.' However, he doesn't think that the EU should have reacted by imposing high tariffs on American goods as a form of revenge. 'Nevertheless, it is a 'win-loss situation'; a win for the US and a loss for Europe. Politically, it is a defeat; economically, it's better than what it may have been,' he says. For the pharma industry, the story is a mixed bag, according to Papandreou, as key aspects remain unclear. 'Therefore, it's too early to determine what will happen to pharma overall. Will this encourage EU investments in the USA? My prediction in this unpredictable situation? Not a cent.' EPP & ND MEP Dimitris Tsiodras also awaits the finalised deal to draw safe conclusions. He recognises, however, that regarding pharmaceuticals, the exemption of certain generics will help ensure the availability of medicines for Greek and European patients and prevent the emergence of further shortages.' [Edited by Brian Maguire]
Euractiv
5 hours ago
- Euractiv
Zelenskyy signs bill restoring independence of anti-corruption agencies
Ukrainian President Volodymyr Zelenskyy signed new legislation on Thursday restoring the independence of Ukraine's anti-corruption agencies, reversing changes that had sparked large-scale protests and criticism from the European Union. Zelenskyy inked the bill shortly after lawmakers gave their backing for the changes, which was also approved in advance by the anti-corruption bodies. Kyiv's European allies supported the new legislation after worrying the previous change to the law would undermine anti-corruption reforms key to Ukraine's bid to join the EU. "The law guarantees the absence of any external influence or interference," the Ukrainian leader wrote on social media, announcing he had approved the bill. "It is very important that the state listens to public opinion. It hears its citizens. Ukraine is a democracy," he added, in an apparent message to Ukrainians who had demanded the changes. The earlier law had put the National Anti-Corruption Bureau of Ukraine (NABU) and Specialised Anti-Corruption Prosecutor's Office (SAPO) under the direct authority of the prosecutor general, who is appointed by the president. Critics took to the streets in protracted protests fearing the the move could facilitate presidential interference in corruption probes. After the vote in parliament on Thursday, Prime Minister Yulia Svyrydenko said that the result was "a clear response to the expectations of society and our European partners". European Commission spokesman Guillaume Mercier said the bill "restored key safeguards" for anti-corruption agencies but cautioned that "this is not the end of the process." "Ukraine accession will require continuous efforts to guarantee a strong capacity to combat corruption and to respect rule of law, we expect Ukraine to deliver on those commitments swiftly," he said.
Euractiv
9 hours ago
- Euractiv
European Commission challenges Hungary's 35-year motorway concession
This article is part of our special report EUYou – Europe is you . Read the original. The Commission's position is that the 35-year contract for construction, operation, and maintenance of Hungary's motorway network did not properly transfer operational risk to the concessionaire - a key factor distinguishing concession contracts from public procurement contracts. As a result, the Commission concluded that the contract was incorrectly classified as a concession rather than a public procurement contract, potentially violating principles of equal treatment and transparency. According to Brussels' investigations, the contract modifications also appear to violate EU regulations regarding public procurement contracts. Even if the agreement were to qualify as a concession, the Commission maintains that its duration exceeds the limits permitted by the Concession Directive. Hungary has been given two months to respond and address the identified deficiencies. The motorway concession was conceived by the Orbán government in 2021. The winning consortium comprised several private equity funds, including Themis, Konzum, Opus Bridge, Opus New Way, Cronus, Vesta, and Via Private Equity Funds. These funds are backed by prominent pro-government business figures László Szíjj and Lőrinc Mészáros. The bidding process, overseen by the National Concession Office under Antal Rogán's supervision, initially had three participants. An Austrian construction group was disqualified due to formal errors, leaving just two contenders. The consortium linked to government-affiliated oligarchs predictably won, with contracts signed after the 2022 elections. Under the arrangement, the consortium pays an annual concession fee of several hundred million forints to the state, while receiving access to the annual motorway maintenance budget, which can reach HUF 200-300 billion. Since 2023, MKIF Magyar Koncessziós Infrastruktúra Fejlesztő Zrt. has been managing motorway maintenance, replacing the state-owned ÁAK. The concession has also limited competition in road construction tenders, as MKIF can award contracts to its own companies without competitive bidding. While the government justified the 35-year concession by citing the ability to secure financing for new motorway sections without increasing state debt, no new construction has begun, and planned projects have been cancelled. The European Commission's assessment suggests the concession procedure was irregular, potentially rendering the current contract invalid. While the contract could be modified through dialogue, the Commission may refer the matter to the European Court of Justice if the government proves unwilling to cooperate.
